Lutetium-177 PSMA radioligand therapy shows promise in metastatic castration-resistant prostate cancer

Pinterest LinkedIn Tumblr +

Radioligand therapy, using targeted prostate-specific membrane antigen (PSMA) compounds, is emerging as a promising treatment option for metastatic castration-resistant prostate cancer, according to a real-world data analysis just published in Targeted Oncology.

The retrospective cohort primary analysis aimed to identify features associated with a response to Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA) radioligand therapy, a subset of theranostics, and greater survival.

According to study co-investigator, Clinical Professor Nat Lenzo, GenesisCare Nuclear Medicine and Internal Medicine Physician: “While increasing evidence supports theranostics as a novel, highly targeted treatment for prostate cancer, there remains a need to better understand how best to predict therapy response and survival outcomes.”

The study surveyed 191 eligible male patients aged 70 years (±8) with metastatic-resistant prostate cancer, who were treated with between one to five cycles of radioligand therapy from November 2015 to February 2019.

Of the 191 men treated during this period, 159 were assessed for the study. A greater than or equal to 50 per cent PSA decline was observed in 89 patients (56 per cent), while any PSA decline occurred in 120 patients (75 per cent).

Notably, the study demonstrated greater efficacy and survival following 177Lu-PSMA radioligand therapy in men with predominantly lymph node metastatic disease, as well as in those with chemotherapy-naïve status and lower levels of baseline prostate-specific antigen (PSA).

“These findings will aid clinicians in identifying patients for whom these treatments may be suitable and in better predicting patient outcomes,” said Clin Prof Lenzo.

GenesisCare Global Chief Medical Officer and Radiation Oncologist, Dr Wally Curran, said: “GenesisCare is committed to providing patients around the world with the best clinical care by leveraging the latest advances in both new technologies and research.

“This study is a significant milestone for men with prostate cancer and is a major step forward in developing the next generation of treatment options,” said Dr Curran.

Paper: Meyrick, D., Gallyamov, M., Sabarimurugan, S. et al. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer. TargOncol (2021).

Source: Sponsored by GenesisCare. For more information, view GenesisCare’s Company Bio page.


About Author

GenesisCare is the largest provider of cancer care in Australia, the United States, the United Kingdom and Spain, and is the leading provider of cardiovascular and sleep treatment throughout Australia. We consist of 5,500 highly trained healthcare professionals and support staff across Australia, the U.K., Spain and the United States, designing innovative treatments and care for people with cancer and heart disease. We provide radiation therapy for more people globally than any other care provider. Across our network, we see more than 400,000 people at more than 440 locations.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.